Background: Our understanding of how testing for and mutations of the BRCA1 and BRCA2
genes affect cancer risk and the use of risk-reduction strategies comes largely from studies …

Introduction Women who have pathogenic mutations in the BRCA1 and BRCA2 genes are
at greatly increased risks for breast and ovarian cancers. Although risk-reduction strategies …

Since the 1990 s discovery of BRCA1 and BRCA2 pathogenic variants in breast or ovarian
cancer patients, genetic testing has been recommended as part of a targeted, individualized …

Background Population-based BRCA1/BRCA2 founder-mutation testing has been
demonstrated as cost effective compared with family history based testing in Ashkenazi …

Simple Summary Identifying BRCA mutations carriers reduces cancer incidence by
surveillance and prevention. We analyzed the cost-effectiveness of population screening …

Purpose The aim of the study was to evaluate the results of a large-scale BRCA1/2 carrier
screening program among Ashkenazi Jewish (AJ) women. Methods We performed a cross …

Genetic counseling is under-utilized in women who meet family history criteria for BRCA1
and BRCA2 (BRCA1/2) testing, particularly among racial/ethnic minorities. We evaluated the …

Abstract BACKGROUND: For BRCA1/BRCA2 gene testing to benefit public health, mutation
carriers must initiate appropriate risk management strategies. There has been little research …

Background The discovery of the BRCA gene in the 1990s created an opportunity for
individualized cancer prevention. BRCA testing in young women before cancer onset …

Individuals who carry BRCA1 or BRCA2 pathogenic variants are recommended to have
extensive cancer prevention screening and risk-reducing surgeries. Uptake of these …